GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans
The DOI matches its Crossref record; 54 of the 56 references it cites were found in a registry or an index.
Abstract
Gut-derived hormones, such as GLP-1, have been proposed to relay information to the brain to regulate appetite. GLP-1 receptor agonists, currently used for the treatment of type 2 diabetes (T2DM), improve glycemic control and stimulate satiety, leading to decreases in food intake and body weight. We hypothesized that food intake reduction after GLP-1 receptor activation is mediated through appetite- and reward-related brain areas. Obese T2DM patients and normoglycemic obese and lean individuals (n = 48) were studied in a randomized, crossover, placebo-controlled trial. Using functional MRI, we determined the acute effects of intravenous administration of the GLP-1 receptor agonist exenatide, with or without prior GLP-1 receptor blockade using exendin 9-39, on brain responses to food pictures during a somatostatin pancreatic-pituitary clamp. Obese T2DM patients and normoglycemic obese versus lean subjects showed increased brain responses to food pictures in appetite- and reward-related brain regions (insula and amygdala). Exenatide versus placebo decreased food intake and food-related brain responses in T2DM patients and obese subjects (in insula, amygdala, putamen, and orbitofrontal cortex). These effects were largely blocked by prior GLP-1 receptor blockade using exendin 9-39. Our findings provide novel insights into the mechanisms by which GLP-1 regulates food intake and how GLP-1 receptor agonists cause weight loss.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1 reduces appetite and food intake through its actions in the CNS.212,260,261”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [212]
In the citing paper
“GLP-1RAs work via numerous mechanisms that contribute to weight loss, one of the most well-known of which is the gut-brain axis.212,213,390”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [212]
In the citing paper
“Incretin therapies work in the appetite and reward circuitries to modulate food intake and energy balance, reducing uncontrollable hunger, overeating, and bulimic symptoms (413), although mechanisms are not completely understood.”
From 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes:Standards of Care in Diabetes—2023 (2023) · cites this paper as [413]
Citations
Cites
IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040
Ogurtsova, K., da Rocha Fernandes, J. D., Huang, Y., Linnenkamp, U., Guariguata, L., Cho, N. H., Cavan, D., Shaw, J. E., & Makaroff, L. E. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.03.024 · Cited by 6,966
Prevalence of Obesity and Trends in the Distribution of Body Mass Index Among US Adults, 1999-2010
Flegal, K. M., Carroll, M. D., Kit, B. K., & Ogden, C. L. (2012) · JAMA · doi:10.1001/jama.2012.39 · Cited by 5,385 · cited 1×
“The global rise in obesity and type 2 diabetes (T2DM) prevalence is a major public health problem (1,2).”
BackgroundIDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030
Whiting, D. R., Guariguata, L., Weil, C., & Shaw, J. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.10.029 · Cited by 3,994
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“GLP-1 stimulates meal-related insulin secretion, inhibits glucagon release, and delays gastric emptying, mechanisms that all contribute to its glucometabolic effects (11).”
BackgroundDeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“The weight reduction seen during GLP-1 receptor agonist treatment is also observed in the absence of nausea (47).”
BackgroundGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“In contrast to previous studies (50), we found no statistically significant effects of GLP-1 receptor activation on scores of hunger, fullness, appetite, prospective food consumption, and desire to eat.”
ResultBaxter, M. G., & Murray, E. A. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn875 · Cited by 1,200 · cited 1×
“The amygdala plays a pivotal role in emotional learning and in the association of cues with reward (33) by encoding the value of the reward predicted by the conditioned stimuli (34).”
BackgroundChanges in brain activity related to eating chocolate: From pleasure to aversion
Small, D. M. (2001) · Brain · doi:10.1093/brain/124.9.1720 · Cited by 1,179 · cited 4×
“The insula is involved in the processing of food-cues and craving for food (31) and has been implicated in the devaluation of food-cues when eating to satiety (32).”
BackgroundInfluentialDrucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 3×
“A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans.”
BackgroundMethodVilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · cited 6×
“Interestingly, GLP-1-receptor agonists have shown modest but consistent weight loss in humans (14).”
BackgroundResultInfluential
Research works printed but not linked: 1
- Wald, 1990, The shortened version of the Dutch translation of the Profile of Mood States (POMS), Ned Tijdschr Psychol, 45, 86
Cited by
Items 301–400 of 498
Yu, Y., Hu, B., Yu, X., Cui, Y., Cao, X., Ni, M.-H., Li, S., Dai, P., Sun, Q., Bai, X., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112175 · Cited by 5
The Role of Insulin Resistance in Cardiorenal Metabolic Syndrome
Xiao, J., Song, W. L., Huang, Y., He, X., Weng, Y., & Yu, H. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001048 · Cited by 5
Ameer, F., Villacres, N. Y., Bustos, D., Shah, P., Appah, N., Luzaya, G. N., Corradi, F., Bakare, I. S., Trujillo, J. V., Mylavarapu, M., et al. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01770-x · Cited by 5
Zhang, S., Niu, S., An, S., Cai, X., & Lao, X. Q. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178587 · Cited by 5
The effect of GLP-1 receptor agonists on anxiety: A systematic review
Yi, Y. T., Zheng, Y. J., Bargiota, S. I., Dri, C. E., Teopiz, K. M., Wong, S., Le, G. H., Kwan, A. T. H., Cao, B., Ho, R., et al. (2026) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2026.107844 · Cited by 5
GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms
Rutigliani, G., Cross, T.-W., de Jong, E., Glover, E. S., Mendoza, I. D., Adisa, M., Tomoo, K., Zhou, X., & Mattes, R. D. (2026) · Obesity Reviews · doi:10.1111/obr.70148 · Cited by 5
“Given increasing use of GLP-1RAs by individuals with lower levels of adiposity [32, 48], further research is needed to determine whether the degree of adiposity alters the efficacy of GLP-1RAs on appetite suppression.”
InfluentialCancela, J. G., Vázquez, O. C., Ledesma, S. N., & Pruimboom, L. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106791 · Cited by 5
Gut Hormones: Possible Mediators of Addictive Disorders?
Nestor, L. J., & Ersche, K. D. (2024) · European Addiction Research · doi:10.1159/000540743 · Cited by 5
“…at the receptor, have been shown to attenuate responses across regions of the reward network during the anticipation of high-calorie food incentives, or the presentation of food stimuli [68, 69], thus suggesting a mechanism by which the GLP-1 system can reduce the incentive value of food reward.”
Tahamata, V. M., Fan, Y., Li, W., Lin, Y.-N., Martínez, R. M., Goh, K. K., Chen, Y., & Chen, C. (2025) · Brain and Behavior · doi:10.1002/brb3.70438 · Cited by 5
New Perspectives on the Development of Antiobesity Drugs
Costantino, L., & Barlocco, D. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.14.167 · Cited by 5
Smits, M. M., ten Kulve, J. S., van Bloemendaal, L., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., IJzerman, R. G., & van Raalte, D. H. (2019) · Nutrition · doi:10.1016/j.nut.2019.06.005 · Cited by 5
Self-citationWeight Regain After GLP-1-Based Therapy Discontinuation: Failure, Physiology, or Follow-Up Gap
Quimbayo-Cifuentes, A. F. (2026) · Cureus · doi:10.7759/cureus.104259 · Cited by 5
Do GLP-1 Receptor Agonists Alter Brain Responses to Reward-Related Cues? A Systematic Review
Dang, V., Sambuco, N., Yammine, L., & Versace, F. (2026) · doi:10.64898/2026.01.31.702984 · Cited by 4
Seijas‐Amigo, J., Salgado‐Barreira, Á., Rodríguez‐Penas, D., Cardeso-Paredes, B., Ribeiro-Ferreiro, M., Rodríguez‐Mañero, M., & González-Juanatey, J. (2026) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-026-02099-y · Cited by 4
Rutigliani, G., & Mattes, R. D. (2026) · Physiology & Behavior · doi:10.1016/j.physbeh.2026.115486 · Cited by 4
Molina‐Castro, M., Rowitz, B. M., & Pepino, M. Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1575156 · Cited by 4
Choi, A. (2022) · Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · doi:10.26685/urncst.415 · Cited by 4
Modulation of brain activity by hormonal factors in the context of ingestive behaviour
Nolde, J. M., Laupenmühlen, J., Al-Zubaidi, A., Heldmann, M., Jauch‐Chara, K., & Münte, T. F. (2019) · Metabolism · doi:10.1016/j.metabol.2019.06.014 · Cited by 4
What can functional brain imaging teach us about remission of type 2 diabetes?
Hirani, D., Alabdulkader, S., Miras, A. D., & Salem, V. (2023) · Diabetic Medicine · doi:10.1111/dme.15235 · Cited by 4
“38 Fewer studies have investigated the effect of insulin resistance per se on neural activity.”
BackgroundA Review of the Effects of Adolescent Cannabis Use on Physical Health
Tuvel, A. L., Winiger, E. A., & Ross, J. M. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.03.005 · Cited by 4
Neural Correlates of Anti-appetite Medications: An fMRI Meta-analysis
Yeung, A. W. K. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210914142227 · Cited by 4
“Visual Medicated Thomas et al. (2018) [35] 24 100.0 Healthy Metachloro- phenylpiperazine Placebo Oral intake 2- 3 h before scan 30 mg (single dose) No Visual Both von Bloemendaal et al. (2014) [37] 48 50.0 Healthy to Type 2 diabetes Exendin 9- 39; exenatide Placebo Intravenous injection throughout the scan Exendin 9-3…”
InfluentialMa, W., Zhang, B., & Chen, X. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14372 · Cited by 4
“After intravenous injection of exenatide in obese (with normal blood glucose) and patients with type 2 diabetes mellitus, the response to food in the brain ’ s insula, amygdala, putamen, and orbito-frontal cortex (involved in feeding and reward behavior) regions decreases 8 .”
Lu, Y., Tang, H., Kotecha, P., Cho, H., Donahoo, W. T., Bian, J., & Guo, J. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15822 · Cited by 3
Szostak, B., Kułaga, M., Kasprzak, A., Grzybek, M., Mazur-Lesińska, D., Wielgosz-Biała, S., Tyszkiewicz, K., Łozowski, B., Kasprzak, M., & Wilczyńska, B. (2025) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.361 · Cited by 3
Qi, W., Boca, S. M., Boianelli, A., Fredberg, M., Lundqvist, S., Davies, G., Field, J., Brighton, C. A., Snijder, A., Grundevik, P., et al. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103683 · Cited by 3
Post-bariatric surgery quality-of-life decline: analysis of the gut–brain axis
Jiao, Y., Zhu, S., Xue, H., Wang, Y., Wang, Y., & Hou, D. (2025) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-025-01784-7 · Cited by 3
Abdulkarim, M., Neto, C., Laffleur, F., Ramos-Pérez, V., Bernkop‐Schnürch, A., Borrós, S., & Gumbleton, M. (2025) · RSC Pharmaceutics · doi:10.1039/d4pm00202d · Cited by 3
“11,12 Currently, only one of the six marketed GLP-1 agonist products is administered orally (semaglutide) 13,14 with a reported extent of bioavailability of 1%.”
Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape
Mondoh, A., Crotty, M., & le Roux, C. W. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2601060 · Cited by 3
“At the central level, semaglutide stimulates pro-opiomelanocortin/cocaine-and amphetamine-regulated transcript (POMC/CART) neurons while inhibiting orexigenic neuro-peptide Y/agouti-related peptide (NPY/AgRP) neurons within the arcuate nucleus of the hypothalamus [20,22].”
Ferrulli, A., Senesi, P., Sonaglioni, A., Cannavaro, D., Massarini, S., Macrì, C., Cipponeri, E., DeFronzo, R. A., & Luzi, L. (2025) · Obesity · doi:10.1002/oby.70105 · Cited by 3
Kuckuck, S., van Gerwen, N., Oosterman, J. E., Savas, M., Kavousi, M., Penninx, B. W. J. H., Boon, M. R., & van Rossum, E. F. C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70393 · Cited by 3
“As GLP-1 analogues affect signalling of various brain regions (notably including the amygdala and the dopaminergic system which are heavily involved in emotional regulation), 44,45 it is conceivable that they may directly affect mental health via their central effects.”
Retrospective chart review on psychiatric manifestations of GLP-1 agonist usage
Sa, B., Maristany, A. J., Subramaniam, A., Kumbkarni, N., Lange, R., Oldak, S. E., Buciuc, A. G., & Padilla, V. L. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.01.042 · Cited by 3
Mack, I., Kullmann, S., de Sequeira, C. L. M., Klos, B., Zipfel, S., Birkenfeld, A. L., & Erschens, R. S. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10047-4 · Cited by 3
Basta, D., Refaei, A. H. A., Msinjili, L., Frishman, W. H., & Lebovics, E. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001298 · Cited by 3
GLP-1 receptor agonists in addiction and affective disorders: Implications for dual disorders
Seijas‐Amigo, J., Salgado‐Barreira, Á., Eiras, S., Arias-Rivas, S., Rodríguez-Carnero, G., & González‐Juanatey, J. R. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111802 · Cited by 3
Kuryłowicz, A., & Czupryniak, L. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71226 · Cited by 3
Huang, J., Hua, F., Jiang, X., Zhang, X., Yang, M., Wang, L., Huang, X., & Luo, K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1130470 · Cited by 3
“The activation of GLP-1 receptors in the human brain helps to regulate appetite and food reward (25, 26).”
BackgroundFloresta, G., Arillotta, D., Catalani, V., Pelletier, G. D. P., Corkery, J., Guirguis, A., & Schifano, F. (2024) · Scientia Pharmaceutica · doi:10.3390/scipharm92020017 · Cited by 3
Novel Pharmacological Agents for the Treatment of Cocaine Use Disorder
Hadizadeh, H., Flores, J. M., Nunes, E. J., Mayerson, T. F., Potenza, M. N., & Angarita, G. A. (2022) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-022-00246-z · Cited by 3
Effects of Vagotomy and Fenugreek on Hyperlipidemia and Insulin Resistance
Khound, R. (2017) · Lincoln (University of Nebraska) · Cited by 3
Kewan, A., Shimatani, T., Saneyasu, T., Kamisoyama, H., & Honda, K. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.136362 · Cited by 3
Obesity: a disease of the ponderostat and the regulation of energy balance
Buscemi, S., Buscemi, C., Colombrita, P., Randazzo, C., Barile, A. M., & Arnaldi, G. (2025) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-025-01790-9 · Cited by 2
Effects of GLP-1 receptor agonists and dual incretin agonists on adipocyte type and size
Turashvili, N. (2025) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2025.101452 · Cited by 2
Maier, G. A., Hennig, B., Rathmann, W., & Kuss, O. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70523 · Cited by 2
Feraco, A., Camajani, E., Muscogiuri, G., Barrea, L., Colao, A., & Caprio, M. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00695-7 · Cited by 2
The Potential of Glucagon-like Peptide-1 Receptor Agonists in Addictive Disorders
Breit, S. (2025) · Medical Research Archives · doi:10.18103/mra.v14i2.7249 · Cited by 2
Effects of Bariatric Surgery and Obesity Medicines on Human Eating Behavior
Hernández, F. C., Villelabeitia, I. K., Levine, I., le Roux, C. W., Miras, A. D., & Price, R. K. (2026) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-070225-105258 · Cited by 2
Myśliwczyk, D., Gofron, K. K., Wasilewski, A., Myśliwiec, M., & Wasilewska, E. (2026) · Nutrients · doi:10.3390/nu18111662 · Cited by 2
“Given GLP-1’s central effects on appetite regulation, reward pathways, and satiety [7,41], future pediatric trials should incorporate standardized dietary assessment (e.g., dietary records/recalls with defined methodology), validated measures of eating behavior, and harmonized reporting of…”
Phenotypic and genomic frameworks for precision pharmacotherapy in obesity: a narrative review
López-Delgado, D. S., Reyes-Zermeño, M. G., Lemus, E. D. S., Acosta-Celis, C. G., Kantún-Marín, M. A., Gomez-Lujan, M., Fallaza-Moya, K., Muñoz-Chuquilín, O., Levano, S. E. T., Gutierrez-Chavez, G., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1803474 · Cited by 2
“…that GLP-1 receptor activation modulates brain regions involved in appetite and reward, including the insula, amygdala, orbitofrontal cortex, ventral tegmental area, and nucleus accumbens, reducing food cue-related neural activity, food intake, and the hedonic value of palatable foods (52, 53).”
Gill, H., Lieberman, J. M., Vincenzo, J. D. D., Rodrigues, N. B., Mansur, R. B., Mckenzie, A., Phan, L., Rosenblat, J. D., & McIntyre, R. S. (2022) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-022-00281-3 · Cited by 2
Is endogenous GLP-1 a major influence on the orbitofrontal cortex?
May-Zhang, A. A., & Woods, S. C. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.09.011 · Cited by 2
Selvarajah, D., Choudhary, P., & Farooqi, I. S. (2014) · Diabetes · doi:10.2337/db14-1311 · Cited by 2
La ciencia detrás de las saciedades
Universidad Favaloro, A., & Katz, M. (2021) · Journal of Behavior and Feeding · doi:10.32870/jbf.v1i1.12 · Cited by 2
Maintaining Fat-Free Mass and Muscle Mass during obesity therapy with Incretin-Mimetic Drugs
Popiela, D., Urbańska, K., Stojak, Ł., Grego, M., Kwiatkowski, F., Baczewski, M., Grego, K., & Czyż, W. (2025) · Quality in Sport · doi:10.12775/qs.2025.37.57000 · Cited by 1
Ohara, M., Yokoyama, H., Seino, H., Fujikawa, T., Kohata, Y., Takahashi, N., Irie, S., Terasaki, M., Mori, Y., Fukui, T., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01691-y · Cited by 1
Miller, C. K., Young-Hyman, D. L., Wooldridge, J. S., Piatt, G., & Hawkins, J. (2025) · Clinical Diabetes · doi:10.2337/cd25-0020 · Cited by 1
A Case of Paradoxical Appetite Increase During Semaglutide Therapy
Karisik, E., Stanojević-Ristić, Z., Јаnkovic, S., Božić, B., Djukanović, M., Halo, E., & Mulić, M. (2025) · Diabetology · doi:10.3390/diabetology6100101 · Cited by 1
Hirai, T., Kitada, M., Endo, K., Hayashi, K., & Suzuki, T. (2025) · Cureus · doi:10.7759/cureus.96335 · Cited by 1
“GLP-1 RAs are known to modulate eating behaviors through various central and peripheral mechanisms, including enhanced satiety, suppressed appetite and hunger, reduced preference for energy-dense foods, and alterations in food-reward pathways [12-14].”
Yan, Q., Shah, M. W., Yang, J., Pan, D., & Sun, G. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1691302 · Cited by 1
Glucagon-Like Peptide-1 Receptor Agonists: A Novel Indication for Substance Use Disorders?
Ftiha, F., Ftiha, J., Parikh, M. A., Frishman, W. H., & Peterson, S. J. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001145 · Cited by 1
Insights into the mechanisms of body weight control
Pereira, S. (2025) · AJP Advances in Physiology Education · doi:10.1152/advan.00091.2025 · Cited by 1
Marano, G., Rossi, S., Lisci, F. M., Traversi, G., Mazza, O., Claro, A. E., Pola, R., Pitocco, D., Sani, G., Gaetani, E., et al. (2025) · Aging advances. · doi:10.4103/agingadv.agingadv-d-25-00027 · Cited by 1
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Management of Diabetes Mellitus: A Review
Singh, V., Yadav, V., Awasthi, V., Yadav, R., Shukla, S., Gupta, D., & Shukla, A. K. (2025) · Journal for Research in Applied Sciences and Biotechnology · doi:10.55544/jrasb.4.6.15 · Cited by 1
Bi, Z., Jiao, Z., Li, J., & Fang, Z. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-08016-x · Cited by 1
“Semaglutide is considered to exert stronger central effects, whereas liraglutide and dulaglutide possess distinct mechanisms of action, potentially leading to non-uniform emotional effects [41, 45].”
Targeting Multiple Gut‐Brain Pathways in Obesity: Rationale for Combination Pharmacotherapy
Miras, A. D., & Hussain, M. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70141 · Cited by 1
“The GLP‐1 receptor agonist exenatide versus placebo also led to a 23% reduction in energy intake among patients with and without obesity and a 14% reduction among patients with type 2 diabetes compared with placebo [66].”
Abenavoli, L., Loricchio, A. G., Lopez, I., Morano, D., Ismaiel, A., Dumitrascu, D. L., & Luzza, F. (2026) · Medicina · doi:10.3390/medicina62050986 · Cited by 1
“Furthermore, these agents reduce food cravings and enhance the hedonic response to eating [23].”
Caplin, A., & Fraser, R. I. (2026) · The Canadian Journal of Addiction · doi:10.1097/cxa.0000000000000268 · Cited by 1
Unravelling obesity: from leptin to glucagon-like peptide-1 receptor agonists
Idowu, T. O., & Chmurzyńska, A. (2026) · Journal of Applied Genetics · doi:10.1007/s13353-026-01084-5 · Cited by 1
Bergia, R. E., Brown, A. W., Braun, M. M., & Messina, M. J. (2026) · Advances in Nutrition · doi:10.1016/j.advnut.2026.100689 · Cited by 1
“By quieting the food noise [14] and altering reward responsivity [29,30], EOMs may rebalance choice in favor of options that align with long-standing dietary guidance.”
Du, J., Yang, Z., & Chen, Y. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1870484 · Cited by 1
Quan, A. T., Nguyen, H. L., & Tran, M. T. N. (2026) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2026.103466 · Cited by 1
Schifano, F., Luca, M. A. D., Bonaccorso, S., Arillotta, D., Floresta, G., Martinotti, G., Papanti, G. D., Corkery, J., Chiappini, S., & Guirguis, A. (2026) · Current Psychiatry Reports · doi:10.1007/s11920-026-01709-w · Cited by 1
Mallardo, M., Messina, A., Monda, V., Marra, M. L., Monda, A., Allocca, S., Casillo, M., Maio, G. D., Perrone, P., Daniele, A., et al. (2026) · Nutrients · doi:10.3390/nu18172748 · Cited by 1
“Beyond their peripheral metabolic effects, GLP-1–based medications also act on central nervous system pathways involved in appetite regulation, satiety, food reward, and food-cue reactivity [167].”
Sorić, T., Sarić, A., Ivanišin, A., Lovrić, M., Milić, M., Matovinović, M., & Sarić, M. M. (2026) · Nutrients · doi:10.3390/nu18172757 · Cited by 2
Food noise: A theoretical review
Wylie, F., Mahmut, M. K., Francis, H., Davidson, T., & Stevenson, R. J. (2026) · Appetite · doi:10.1016/j.appet.2026.108791 · Cited by 1
Prevention and Treatment of Childhood Obesity and Metabolic Syndrome
Roy, S. M., Rustico, S. E., & Kublaoui, B. M. (2015) · Springer eBooks · doi:10.1007/978-3-319-12125-3_46-1 · Cited by 1
Efecto de la formulación de galletas en la secreción de hormonas de saciedad
Martínez-Sáez, N., Hochkogler, C. M., Somoza, V., & del Castillo, M. D. (2016) · INNOTEC · doi:10.26461/11.09 · Cited by 1
The Endocrine Regulation of Energy and Body Weight
Preiato, V. L., Vicennati, V., Gambineri, A., & Pagotto, U. (2018) · Endocrinology · doi:10.1007/978-3-319-44675-2_22 · Cited by 1
Glucagon-Like Peptide 1 and Human Obesity
Anandhakrishnan, A., & Korbonits, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48559-3.00003-8 · Cited by 1
Neuroendocrinology of Energy Homeostasis
Preiato, V. L., Vicennati, V., Garelli, S., & Pagotto, U. (2017) · Endocrinology · doi:10.1007/978-3-319-38681-2_16-1 · Cited by 1
The regulation of appetite by gut hormones
Spreckley, E. (2015) · doi:10.25560/56218 · Cited by 1
The Effect of High-Intensity Interval Training on GLP-1, Appetite, and Weight in Obese Rats
Sepehri, H., Nemati, J., Jahromi, M. K., Eskandari, M. H., & Daryanoosh, F. (2021) · مجله علمی پزشکی جندی شاپور · doi:10.32598/jsmj.20.3.1975 · Cited by 1
Neuroendocrinology of Energy Homeostasis
Preiato, V. L., Vicennati, V., Garelli, S., & Pagotto, U. (2018) · Endocrinology · doi:10.1007/978-3-319-44444-4_16 · Cited by 1
Medicatie voor obesitas: vooruitgang en uitdagingen
Muskiet, M. H. A., & Boon, M. R. (2024) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-024-1569-4 · Cited by 1
Glucagon-like peptide-1 and alcohol-mediated behaviors in rodents
Vallöf, D. (2019) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 1
Brain-based Etiology of Weight RegulationPreprint
Burger, K. S., & Sadler, J. R. (2017) · NutriXiv (OSF Preprints) · doi:10.31232/osf.io/yq2cz · Cited by 1
Handley, D., Almansoori, S., Sato, M. S., Amin, H. A., Alsters, S., Chahal, H., Purkayastha, S., Murphy, K. G., van Haelst, M. M., le Roux, C. W., et al. (2023) · medRxiv · doi:10.1101/2023.05.22.23290347 · Cited by 1
The psychology of mukbang watching: can watching others eat be addictive?
Kırcaburun, K. (2024) · Nottingham Trent University's Institutional Repository (Nottingham Trent Repository) · Cited by 1
Anyiam, O. (2025) · Nottingham ePrints (University of Nottingham) · Cited by 1
SMELTZER, J. T. (2023) · eScholarship (California Digital Library) · Cited by 1
Murugadoss, K., Venkatakrishnan, A., & Soundararajan, V. (2026) · medRxiv · doi:10.64898/2026.04.16.26351060 · Cited by 1
ten Kulve, J. S. (2016) · Pure Amsterdam UMC
The Influence of Stress on Obesity Development in Children
Goran, M. I. (2016) · CRC Press eBooks · doi:10.1201/9781315370958-19
Glucagon-like peptide (GLP)-1 analogues for normoglycaemic, overweight or obese adults
Mazzucca, A. C. P., Parra, M. T., Latorraca, C. O., Spinola‐Castro, A. M., & Riera, R. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012793
RetractedMaciel, M. G. (2017) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
The brain – gut interaction: defining the role of the nutrient-induced human brain activation matrix
Zanchi, D. (2018) · edoc (University of Basel) · doi:10.5451/unibas-006798095
Triplitt, C. L. (2019) · Cambridge University Press eBooks · doi:10.1017/9781107706866.028
THE EFFECTS OF OAT β-GLUCAN CONSUMPTION ON THE ENERGY INTAKES OF HEALTHY INDIVIDUALS
Zaremba, S. (2018) · Queen Margaret University Publications Repository (Queen Margaret University)
Incretin Therapies: Current Use and Emerging Possibilities
Schlögl, H., & Stümvoll, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_33
The mechanism of energy expenditure of oxyntomodulin
Scott, R. (2017) · Spiral (Imperial College London) · doi:10.25560/68291
Metadata
- Authors
- van Bloemendaal, L., IJzerman, R. G., ten Kulve, J. S., Barkhof, F., Konrad, R. J., Drent, M. L., Veltman, D. J., & Diamant, M.
- Affiliations
- Diabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, the Netherlands
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Eli Lilly (United States) (US)
- Amsterdam Neuroscience (NL)
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-11-13
- Volume
- 63
- Issue
- 12
- Pages
- 4186-4196
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2018940614
- Cited by
- 427
- References
- 56
- Citations by year
- 2026: 52 · 2025: 60 · 2024: 44 · 2023: 39 · 2022: 25 · 2021: 35 · 2020: 28 · 2019: 25 · 2018: 22 · 2017: 30 · 2016: 34 · 2015: 29 · 2014: 4
- FWCI
- 15.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- VU Research Portal (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, exenatide, exendin-9-39, appetite regulation, food reward, food images, obesity, type 2 diabetes, satiety, insula, amygdala, orbitofrontal cortex, putamen, weight loss
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Adult, Aged, Amygdala, Appetite, Brain, Cerebral Cortex, Diabetes Mellitus, Type 2, Feeding Behavior, Female, Humans, Hypoglycemic Agents, Magnetic Resonance Imaging, Male, Middle Aged, Obesity, Peptide Fragments, Peptides, Photic Stimulation, Putamen, Reward, Venoms, Case-Control Studies, Prefrontal Cortex, Receptors, Glucagon, Cross-Over Studies, Functional Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.